Burns J, Landorf K B, Ryan M M, Crosbie J, Ouvrier R A
Children's Hospital at Westmead Clinical School, University of Sydney, Institute for Neuromuscular Research, Locked Bag 4001, Westmead, Sydney, New South Wales, Australia, 2145.
Cochrane Database Syst Rev. 2007 Oct 17;2007(4):CD006154. doi: 10.1002/14651858.CD006154.pub2.
People with pes cavus frequently suffer foot pain, which can lead to significant disability. Despite anecdotal reports, rigorous scientific investigation of this condition and how best to manage it is lacking.
To assess the effects of interventions for the prevention and treatment of pes cavus.
We searched the Cochrane Neuromuscular Disease Group Trials Register (April 2007), MEDLINE (January 1966 to April 2007), EMBASE (January 1980 to April 2007), CINAHL (January 1982 to April 2007), AMED (January 1985 to April 2007), all EBM Reviews (January 1991 to April 2007), SPORTdiscuss (January 1830 to April 2007) and reference lists of articles. We also contacted known experts in the field to identify additional published or unpublished data.
We included all randomised and quasi-randomised controlled trials of interventions for the treatment of pes cavus. We also included trials aimed at preventing or correcting the cavus foot deformity.
Two authors independently selected papers, assessed trial quality and extracted data.
Only one trial (custom-made foot orthoses) fully met the inclusion criteria. Two additional cross-over trials (off-the-shelf foot orthoses and footwear) were also included. Both studies assessed secondary biomechanical outcomes less than three-months after randomisation. Data used in the three studies could not be pooled due to heterogeneity of diagnostic groups and outcome measures. The one trial that fully met the inclusion criteria investigated the treatment of cavus foot pain in 154 adults over a three month period. The trial showed a significant reduction in the level of foot pain, measured using the validated 100-point Foot Health Status Questionnaire, with custom-made foot orthoses versus sham orthoses (WMD 10.90; 95% CI 3.21 to 18.59). Furthermore, a significant improvement in foot function measured with the same questionnaire was reported with custom-made foot orthoses (WMD 11.00; 95% CI 3.35 to 18.65). There was also an increase in physical functioning of the Medical Outcomes Short Form - 36 (WMD 9.50; 95% CI 4.07 to 14.93). There was no difference in reported adverse events following the allocation of custom-made (9%) or sham foot orthoses (15%) (RR 0.61; 95% CI 0.26 to 1.48).
AUTHORS' CONCLUSIONS: In one randomised controlled trial, custom-made foot orthoses were significantly more beneficial than sham orthoses for treating chronic musculoskeletal foot pain associated with pes cavus in a variety of clinical populations. There is no evidence for any other type of intervention for the treatment or prevention of foot pain in people with a cavus foot type.
高弓足患者经常遭受足部疼痛,这可能导致严重的残疾。尽管有一些传闻报道,但对这种情况及其最佳治疗方法缺乏严格的科学研究。
评估预防和治疗高弓足的干预措施的效果。
我们检索了Cochrane神经肌肉疾病组试验注册库(2007年4月)、MEDLINE(1966年1月至2007年4月)、EMBASE(1980年1月至2007年4月)、CINAHL(1982年1月至2007年4月)、AMED(1985年1月至2007年4月)、所有循证医学综述(1991年1月至2007年4月)、SPORTdiscuss(1830年1月至2007年4月)以及文章的参考文献列表。我们还联系了该领域的知名专家,以确定其他已发表或未发表的数据。
我们纳入了所有治疗高弓足干预措施的随机和半随机对照试验。我们还纳入了旨在预防或矫正高弓足畸形的试验。
两位作者独立选择论文、评估试验质量并提取数据。
只有一项试验(定制足部矫形器)完全符合纳入标准。另外两项交叉试验(现成的足部矫形器和鞋类)也被纳入。两项研究均在随机分组后不到三个月的时间内评估了次要生物力学结果。由于诊断组和结局测量的异质性,三项研究中使用的数据无法合并。完全符合纳入标准的一项试验在三个月内对154名成年人的高弓足疼痛治疗进行了研究。该试验表明,使用经过验证的100分足部健康状况问卷测量,定制足部矫形器与假矫形器相比,足部疼痛水平显著降低(加权均数差10.90;95%可信区间3.21至18.59)。此外,使用相同问卷测量,定制足部矫形器报告足部功能有显著改善(加权均数差11.00;95%可信区间3.35至18.65)。医学结局简表-36的身体功能也有所增加(加权均数差9.50;95%可信区间4.07至14.93)。定制(9%)或假足部矫形器(15%)分配后报告的不良事件没有差异(风险比0.61;95%可信区间0.26至1.48)。
在一项随机对照试验中,对于治疗各种临床人群中与高弓足相关的慢性肌肉骨骼足部疼痛,定制足部矫形器比假矫形器明显更有益。没有证据表明任何其他类型的干预措施可用于治疗或预防高弓足型患者的足部疼痛。